Exelixis (NASDAQ: EXEL) stock had been in the doldrums ... for for HCC indication in the first quarter of 2018. To know why Exelixis' rebound is just getting started, it's important to understand why the stock dipped in the first place.
Just look at the number of running backs racking up touches and averaging a …
For a more complex plan, you can use online tools like Mint.com, Quicken, or even a simple spreadsheet. Remember that if you use ... Consider creating a donor …
Growth stocks can be some of the most exciting picks in the market, as these high-flyers can captivate investors’ attention, and produce big gains as well. However, these can also lead on the downside when the growth story is over, …
IONS closed Tuesday's trading at $50.93, down 2.60%. In after-hours, the stock gained 1.90% to $51.90. Exelixis Inc.'s (EXEL) supplemental New Drug Application for CABOMETYX as first-line monotherapy for advanced renal cell …
Advance refundings double the stock of tax-exempt bonds for a single project ... Win Smith is the founder of Win Analytics and blogs at The Well-Tempered …
"The EXEL Industries Group had a great 2016-2017 in terms of growth, profitability and cash generation. We continue to pursue our objective of sustainable and profitable growth and have reached a new milestone this year, with an operating …
Sales for the 2016-2017 fiscal year totaled €874.2 million, up 13.4%. This increase came from Sugar Beet Harvester …
MENAFN1mon